{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:21:24Z","timestamp":1791426084030,"version":"4.3.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,6,28]],"date-time":"2015-06-28T00:00:00Z","timestamp":1435449600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13722-015-0037-2","type":"journal-article","created":{"date-parts":[[2015,6,27]],"date-time":"2015-06-27T17:03:47Z","timestamp":1435424627000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The management of opiate use disorders in France: results of an observational survey of general practitioners"],"prefix":"10.1186","volume":"10","author":[{"given":"Pierre","family":"Polom\u00e9ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Bronner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9deric","family":"Fry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Ravoninjatovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lina","family":"Fatseas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,28]]},"reference":[{"key":"37_CR1","first-page":"363","volume":"48","author":"A Duburcq","year":"2000","unstructured":"Duburcq A, Charpak Y, Blin P, Madec L. Two years follow-up of a heroin users cohort treated with high dosage buprenorphine. Results of the SPESUB study (pharmacoepidemiologic follow-up of general practice Subutex). Rev Epidemiol Sante Publique. 2000;48:363\u201373.","journal-title":"Rev Epidemiol Sante Publique"},{"key":"37_CR2","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.pharma.2009.05.007","volume":"67","author":"C Gatignol","year":"2009","unstructured":"Gatignol C. Opiate replacement therapy in France. Ann Pharm Fr. 2009;67:360\u20134.","journal-title":"Ann Pharm Fr"},{"key":"37_CR3","unstructured":"Observatoire fran\u00e7ais des drogues et des toxicomanies: Drogues Chiffres Cl\u00e9s. 4e Ed. \n                    http:\/\/www.ofdt.fr\/BDD\/publications\/docs\/dcc2012.pdf\n                    \n                  . 2012: Accessed October 17, 2014."},{"key":"37_CR4","unstructured":"Costes J-M, Vaissade L, Colasante E, Palle C, Legleye S, Janssen E, et al. Pr\u00e9valence de l\u2019usage probl\u00e9matique de drogues en France - estimations 2006. \n                    http:\/\/www.ofdt.fr\/BDD\/publications\/docs\/epfxjcp6.pdf\n                    \n                  . 2009: Accessed October 17, 2014."},{"key":"37_CR5","unstructured":"European Monitoring Centre for Drugs and Drug Addiction: 2011 Annual report on the state of the drugs problem in Europe. \n                    http:\/\/www.emcdda.europa.eu\/publications\/annual-report\/2011\n                    \n                  . 2011: Accessed October 17, 2014."},{"key":"37_CR6","first-page":"177","volume-title":"Barom\u00e8tre sant\u00e9 m\u00e9decins g\u00e9n\u00e9ralistes 2009. Saint Denis","author":"R Guignard","year":"2011","unstructured":"Guignard R, Beck F, Obradovic I. Prise en charge des addictions par les m\u00e9decins g\u00e9n\u00e9ralistes. In: INPES, editor. Barom\u00e8tre sant\u00e9 m\u00e9decins g\u00e9n\u00e9ralistes 2009. Saint Denis. 2011. p. 177\u2013201."},{"key":"37_CR7","unstructured":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9: Commission nationale des stup\u00e9fiants et des psychotropes. Compte-rendu de la 86i\u00e8me r\u00e9union du 15 d\u00e9cembre 2009. \n                    http:\/\/ansm.sante.fr\/var\/ansm_site\/storage\/original\/application\/782c00f81619946fdb54bad8ee73b745.pdf\n                    \n                  . 2010: Accessed October 2014."},{"key":"37_CR8","first-page":"4","volume":"43","author":"L Boireau","year":"2011","unstructured":"Boireau L. Les difficult\u00e9s de la substitution aux opiac\u00e9s en m\u00e9decine g\u00e9n\u00e9rale : Etat des lieux dans le d\u00e9partement de la Loire en 2009 et \u00e9tude qualitative : Th\u00e8se de M\u00e9decine G\u00e9n\u00e9rale, soutenue le 8\/11\/2010. Le Flyer. 2011;43:4\u20139.","journal-title":"Le Flyer"},{"key":"37_CR9","unstructured":"Observatoire fran\u00e7ais des drogues et des toxicomanies: Substitution aux opiac\u00e9s en France. Synth\u00e8se des informations disponibles de 1996 \u00e0 2001 en France. \n                    http:\/\/www.ofdt.fr\/BDD\/publications\/docs\/epfxofj6.pdf\n                    \n                  . 2003: Accessed October 17, 2014."},{"key":"37_CR10","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s11920-007-0046-2","volume":"9","author":"M Fatseas","year":"2007","unstructured":"Fatseas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Curr Psychiatry Rep. 2007;9:358\u201364.","journal-title":"Curr Psychiatry Rep"},{"key":"37_CR11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.pharma.2009.05.006","volume":"67","author":"L Michel","year":"2009","unstructured":"Michel L. Opioid substitution therapy in France: a physician\u2019s overview. Ann Pharm Fr. 2009;67:369\u201373.","journal-title":"Ann Pharm Fr"},{"key":"37_CR12","unstructured":"Observatoire fran\u00e7ais des drogues et des toxicomanies: 2012 National report (2011 data) to the EMCDDA by the Reitox National Focal Point France. New development, trends and in-depth information on selected issues. [\n                    http:\/\/www.emcdda.europa.eu\/attachements.cfm\/att_213784_EN_Austria_NR2012.pdf\n                    \n                  ]. 2012: Accessed October 17, 2014."},{"key":"37_CR13","first-page":"11","volume-title":"La toxicomanie \u00e0 l\u2019h\u00e9ro\u00efne en m\u00e9decine g\u00e9n\u00e9rale","author":"J Carpentier","year":"1993","unstructured":"Carpentier J. La toxicomanie \u00e0 l\u2019h\u00e9ro\u00efne en m\u00e9decine g\u00e9n\u00e9rale. Paris: Ellipses; 1993. p. 11\u201321."},{"key":"37_CR14","first-page":"224","volume":"42","author":"Y Charpak","year":"1994","unstructured":"Charpak Y, Nory F, Barbot J. Management of drug addicts (heroin addicts) by general practitioners. Rev Epidemiol Publique. 1994;42:224\u201334.","journal-title":"Rev Epidemiol Publique"},{"key":"37_CR15","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1016\/j.socscimed.2007.02.049","volume":"64","author":"A Guichard","year":"2007","unstructured":"Guichard A, Lert F, Brodeur JM, Richard L. Buprenorphine substitution treatment in France: drug users\u2019 views of the doctor-user relationship. Soc Sci Med. 2007;64:2578\u201393.","journal-title":"Soc Sci Med"},{"key":"37_CR16","first-page":"29","volume":"60","author":"P Patrizio Di","year":"2010","unstructured":"Di Patrizio P, Houille S, Schwan R, Boivin JM. Buprenorphin and benzodiazepines, an association with high risk. Reality of co-prescriptions by the general practitioners. Rev Prat. 2010;60:29\u201334.","journal-title":"Rev Prat"},{"key":"37_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11606-010-1461-3","volume":"26","author":"AJ Gordon","year":"2011","unstructured":"Gordon AJ, Kunins HV, Rastegar DA, Tetrault JM, Walley AY. Update in addiction medicine for the generalist. J Gen Intern Med. 2011;26:77\u201382.","journal-title":"J Gen Intern Med"},{"key":"37_CR18","unstructured":"Plancke L, Lose S, Amariei A, Beno\u00eet E, Chantelou M-L. Les traitements de substitution aux opiac\u00e9s en m\u00e9decine de ville dans le Nord - Pas-de-Calais. Lille: Granitea Nord-Pas-de-Calais. \n                    http:\/\/www.federationaddiction.fr\/wp-content\/uploads\/2012\/02\/Rapport_tso_npdc-dec2010.pdf\n                    \n                  . 2010: Accessed October 17, 2014."},{"key":"37_CR19","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1046\/j.1360-0443.1998.9310156714.x","volume":"93","author":"JP Moatti","year":"1998","unstructured":"Moatti JP, Souville M, Escaffre N, Obadia Y. French general practitioners\u2019 attitudes toward maintenance drug abuse treatment with buprenorphine. Addiction. 1998;93:1567\u201375.","journal-title":"Addiction"},{"key":"37_CR20","unstructured":"Cadet-Ta\u00efrou A, Cholley D. Approche r\u00e9gionale de la substitution aux opiac\u00e9s (1999\u20132002) - Pratiques et disparit\u00e9s r\u00e9gionales. \n                    http:\/\/www.ofdt.fr\/BDD\/publications\/docs\/epfxack6.pdf\n                    \n                  ]. 2004: Accessed October 17, 2014."},{"key":"37_CR21","first-page":"444","volume":"55","author":"J Strang","year":"2005","unstructured":"Strang J, Sheridan J, Hunt C, Kerr B, Gerada C, Pringle M. The prescribing of methadone and other opioids to addicts: national survey of GPs in England and Wales. Br J Gen Pract. 2005;55:444\u201351.","journal-title":"Br J Gen Pract"},{"key":"37_CR22","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1071\/PY11100","volume":"18","author":"C Longman","year":"2012","unstructured":"Longman C, Temple-Smith M, Gilchrist G, Lintzeris N. Reluctant to train, reluctant to prescribe: barriers to general practitioner prescribing of opioid substitution therapy. Aust J Prim Health. 2012;18:346\u201351.","journal-title":"Aust J Prim Health"},{"key":"37_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1747-597X-8-26","volume":"8","author":"B Schulte","year":"2013","unstructured":"Schulte B, Schmidt CS, Kuhnigk O, Schafer I, Fischer B, Wedemeyer H, et al. Structural barriers in the context of opiate substitution treatment in Germany\u2014a survey among physicians in primary care. Subst Abuse Treat Prev Policy. 2013;8:26.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"37_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000320576","volume":"17","author":"H Stover","year":"2011","unstructured":"Stover H. Barriers to opioid substitution treatment access, entry and retention: a survey of opioid users, patients in treatment, and treating and non-treating physicians. Eur Addict Res. 2011;17:44\u201354.","journal-title":"Eur Addict Res"},{"key":"37_CR25","first-page":"73","volume":"2","author":"A Grand-Filaire","year":"1993","unstructured":"Grand-Filaire A, Grand A. Les m\u00e9decins g\u00e9n\u00e9ralistes face aux conduites toxicomaniaques. Sant\u00e9 Publique. 1993;2:73\u201381.","journal-title":"Sant\u00e9 Publique"},{"issue":"Suppl A","key":"37_CR26","first-page":"A27","volume":"151","author":"M Ducla De","year":"2000","unstructured":"De Ducla M, Gagnon A, Mucchielli A, Robinet S, Vellay A. Follow-up of opioid addicts treated with high-dose buprenorphine in a health care network. National retrospective study. Experience of French general physicians. Ann Med Interne. 2000;151(Suppl A):A27\u201332.","journal-title":"Ann Med Interne"},{"key":"37_CR27","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.lpm.2012.07.038","volume":"41","author":"D Touzeau","year":"2012","unstructured":"Touzeau D, Courty P. Opiates, harm reduction and polysubstance abuse. Presse Med. 2012;41:1192\u2013200.","journal-title":"Presse Med"},{"key":"37_CR28","doi-asserted-by":"publisher","first-page":"4S44","DOI":"10.1016\/S0399-8320(07)92563-4","volume":"31","author":"P Chossegros","year":"2007","unstructured":"Chossegros P. Management of drug addiction in France (a short history). Gastroenterol Clin Biol. 2007;31:4S44\u201350.","journal-title":"Gastroenterol Clin Biol"}],"container-title":["Addiction Science & Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-015-0037-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13722-015-0037-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-015-0037-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-015-0037-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T22:42:46Z","timestamp":1553640166000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-015-0037-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,28]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["37"],"URL":"https:\/\/doi.org\/10.1186\/s13722-015-0037-2","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,28]]},"assertion":[{"value":"19 January 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"16"}}